Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Bullish +65

Piper Sandler and Morgan Stanley Highlight Amgen (AMGN) on Pipeline Strength and Obesity Drug Potential

📈 Piper Sandler reaffirmed an Overweight rating and $427 price target for Amgen Inc. (NASDAQ: AMGN).

📈 Morgan Stanley maintained its Overweight rating and increased its price objective to $340 from $332.

💊 Dazodalibep is a CD40 ligand-directed fusion protein for Sjogren's syndrome with Phase III trials concluding in late 2026.

🔬 Amgen is researching dazodalibep across two categories: moderate-to-severe symptoms and systemic disease activity.

🤝 Morgan Stanley notes that Amgen's portfolio is bolstered by its recent acquisition of Horizon.

⚖️ MariTide is identified as a major focus within Amgen's pipeline for obesity treatment.

🏢 Amgen Inc. was founded in 1980 and is headquartered in California.

Bullish Signals
  • Piper Sandler reaffirmed its Overweight rating with a $427 price target, signaling strong institutional confidence in the company's current valuation.
  • Morgan Stanley increased its price objective to $340 from $332, indicating a positive revision based on recent corporate developments.
  • The upcoming Phase III conclusion for dazodalibep in late 2026 represents a significant potential milestone for Amgen's immunology division.
  • Amgen's acquisition of Horizon is viewed as a strategic move to bolster its portfolio of cutting-edge medications.
  • MariTide is highlighted as a major focus area, suggesting strong analyst interest in the company's obesity drug potential.
Full Analysis
Piper Sandler and Morgan Stanley have reaffirmed their Overweight ratings on Amgen Inc. (NASDAQ: AMGN), citing the strength of its pharmaceutical pipeline and potential in obesity therapeutics. Piper Sandler maintained a $427 price target, while Morgan Stanley raised its objective to $340 from $332 following the company's acquisition of Horizon. Analysts highlight dazodalibep, a CD40 ligand-directed fusion protein for Sjogren's syndrome, as an underappreciated asset with Phase III trials concluding in late 2026. The drug targets both moderate-to-severe symptoms and systemic disease activity, bolstering Amgen's immunology portfolio. Morgan Stanley emphasizes MariTide, a major focus within the company's pipeline for obesity treatment, as a key driver for future stock performance. While acknowledging investment risks, analysts view these developments as significant catalysts for Amgen's growth trajectory.